Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
NCT ID: NCT01915212
Last Updated: 2026-01-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
69 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-09-26
Study Completion Date
2017-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
\- Herpes simplex virus type 2 (HSV-2) is a major cause of genital herpes. It can also cause serious infection in newborns and in people with weakened immune systems. It increases the risk of getting an HIV infection and of spreading HIV to someone else. Therefore, a vaccine that could prevent genital herpes could improve the general health of the world s population. Researchers want to study whether a new vaccine, HSV529, which may be used in the future to prevent herpes infections, is safe.
Objectives:
\- To test whether a new herpes vaccine is safe.
Eligibility:
\- Healthy adults 18 40 years old.
Design:
* Participants will have 3 vaccination visits, 7 follow-up visits, and 3 follow-up phone calls over 1 year.
* Each vaccination visit will last about 4 hours.
* Participants will be screened with a medical history and physical exam.
* Participants will have a blood sample taken.
* Participants will be given the vaccine or a placebo, by injection from a needle. They will be monitored for 30 minutes to check for any allergic reaction.
* Participants will be given a diary card to record any symptoms they may feel later.
* At follow-up visits, participants will give a blood sample and answer health questions.
* In the phone calls, participants will answer health questions.
\- Herpes simplex virus type 2 (HSV-2) is a major cause of genital herpes. It can also cause serious infection in newborns and in people with weakened immune systems. It increases the risk of getting an HIV infection and of spreading HIV to someone else. Therefore, a vaccine that could prevent genital herpes could improve the general health of the world s population. Researchers want to study whether a new vaccine, HSV529, which may be used in the future to prevent herpes infections, is safe.
Objectives:
\- To test whether a new herpes vaccine is safe.
Eligibility:
\- Healthy adults 18 40 years old.
Design:
* Participants will have 3 vaccination visits, 7 follow-up visits, and 3 follow-up phone calls over 1 year.
* Each vaccination visit will last about 4 hours.
* Participants will be screened with a medical history and physical exam.
* Participants will have a blood sample taken.
* Participants will be given the vaccine or a placebo, by injection from a needle. They will be monitored for 30 minutes to check for any allergic reaction.
* Participants will be given a diary card to record any symptoms they may feel later.
* At follow-up visits, participants will give a blood sample and answer health questions.
* In the phone calls, participants will answer health questions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
NCT04222985
Genital Herpes
TERMINATED
PHASE1
Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects
NCT00698568
Prophylaxis for Herpes Simplex
COMPLETED
PHASE3
HSV529 Vaccine in HSV-2 Seropositive Adults
NCT02571166
Herpes Simplex Virus 2
COMPLETED
PHASE1
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
NCT00699764
Herpes Simplex
COMPLETED
PHASE3
Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant
NCT00697567
Prophylaxis Herpes Simplex
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Herpes simplex virus 2 (HSV-2) causes genital herpes and increases the risk of acquisition and transmission of HIV. An HSV-2 vaccine is not available. We will study a replication-defective HSV-2 vaccine, HSV529, that is deleted for 2 essential viral proteins, that can infect, but not replicate in normal cells. The goals of the study are to determine (a) the safety of HSV529 vaccine in persons with or without HSV infection, and (b) the ability of the vaccine to elicit immune responses to HSV-2 including virus-specific antibodies and T cell responses to the virus. Three groups of 20 subjects each will be randomized and will receive 3 doses of HSV529 (15 subjects per group) or saline placebo injection (5 subjects per group). Each subject will be followed for 6 months after the last dose of vaccine. The 3 groups will be (a) subjects who were infected with HSV-2 in the past but may or may not have been infected with HSV-1 (HSV-1+/-/HSV-2+), (b) subjects who have been infected only with HSV-1 (HSV-1+/HSV-2-), and (c) subjects who have not been infected with HSV-1 or HSV-2 (HSV-1-/HSV-2-). Vaccine or placebo will be administered on Day 0 and approximately 1 month and 6 months after enrollment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Healthy Volunteers
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HSV529
1 x 107 pfu/dose of HSV529 in 10 mM L-histidine buffer containing 50 mM potassium glutamate, 160 mM sodium chloride, and 10% (w/v) sucrose
Group Type
EXPERIMENTAL
HSV529
Intervention Type
BIOLOGICAL
The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
Placebo
Sodium Chloride 0.9%
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Sodium Chloride 0.9%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HSV529
The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
Intervention Type
BIOLOGICAL
Placebo
Sodium Chloride 0.9%
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
An individual must fulfill all of the following criteria in order to be eligible for trial enrollment:
1. Aged 18 to 40 years on the day of enrollment.
2. In good general health with absence of significant health problems as determined by medical history, physical examination, and laboratory screening performed during screening visits.
3. Subject will reside within a 60 mile or less radius from Bethesda, MD during the period of participation in the trial.
4. Hemoglobin, hematocrit, white blood cell count, platelet count, serum creatinine, and liver function (ALT, AST, alkaline phosphatase, total bilirubin) screening laboratory results do not fall into the range of values that are Grade 1 or greater as per the toxicity grading scale and IgG level greater than or equal to 600 mg/dl.
5. Females subjects must be of non-childbearing potential i.e. surgically sterilized (bilateral tubal ligation, hysterectomy) or, if of child-bearing potential and sexually active with a male partner, she must be willing to use a highly effective method of contraception (e.g., intrauterine device (IUD); oral contraceptives diaphragm or condom in combination with contraceptive foam, jelly or cream; Norplant, DepoProvera, contraceptive skin patch or cervical ring) for at least 30 days prior to vaccination and until 30 days after final vaccination or be in a monogamous relationship with a male partner who has undergone a vasectomy at least 6 months prior to first dose of study agent.
6. Willingness to attend all scheduled visits and able to comply with all trial procedures (e.g., blood draws, completion of diary cards, return for follow-up visits, accessible by phone or pager, able to self-sample for assessment of asymptomatic shedding of HSV, and not planning on moving from study area).
7. Negative HIV test result determined with an approved FDA-approved test. Confirmatory testing may be required based on the initial assay used and the result.
8. Subject is willing not to use antiviral therapy less than or equal to 2 days before and less than or equal to 3 days after each injection.
9. Subject is willing to forgo receipt of a licensed, live vaccine in the 30 days preceding each dose of vaccine or in the 30 days following each dose of vaccine. The inactivated flu vaccine can be used greater than or equal to 14 days before or greater than or equal to 14 days after administration of study vaccine, if this is felt to be necessary.
10. Persons who have close contact with infants or immunocompromised individuals agree to avoid such contact for 3 days after each injection.
11. Subject must be either HSV-1 IgG antibody positive or negative and HSV-2 IgG antibody positive, HSV-1 IgG antibody positive /HSV-2 IgG antibody negative, or HSV-1/HSV-2 IgG antibody negative as determined by an available commercial immunoassay.
12. Subject must be willing to allow storage of blood, swabs of skin or mucosa, biopsies of skin lesions, or, for female subjects, cervicovaginal secretions (if collected) for future research.
Participation of Women:
Contraception: The effects of HSV529 on the developing human fetus are unknown. For this reason, females subjects must be of non-childbearing potential i.e. either surgically sterilized (bilateral tubal ligation, hysterectomy) or, if of child-bearing potential and sexually active with a male partner, she must be willing to use a highly effective method of contraception (e.g., intrauterine device (IUD); oral contraceptives diaphragm or condom in combination with contraceptive foam, jelly or cream; Norplant, DepoProvera, contraceptive skin patch or cervical ring) for at least 30 days prior to vaccination and until 1 month after final vaccination or be in a monogamous relationship with a male partner who has undergone a vasectomy at least 6 months prior to first dose of study agent. Females must have a negative urine pregnancy test result prior to injection with HSV529 or placebo. During the course of the study, if a woman becomes pregnant or suspects she is pregnant, she should inform the study staff and her primary care physician immediately.
1. Aged 18 to 40 years on the day of enrollment.
2. In good general health with absence of significant health problems as determined by medical history, physical examination, and laboratory screening performed during screening visits.
3. Subject will reside within a 60 mile or less radius from Bethesda, MD during the period of participation in the trial.
4. Hemoglobin, hematocrit, white blood cell count, platelet count, serum creatinine, and liver function (ALT, AST, alkaline phosphatase, total bilirubin) screening laboratory results do not fall into the range of values that are Grade 1 or greater as per the toxicity grading scale and IgG level greater than or equal to 600 mg/dl.
5. Females subjects must be of non-childbearing potential i.e. surgically sterilized (bilateral tubal ligation, hysterectomy) or, if of child-bearing potential and sexually active with a male partner, she must be willing to use a highly effective method of contraception (e.g., intrauterine device (IUD); oral contraceptives diaphragm or condom in combination with contraceptive foam, jelly or cream; Norplant, DepoProvera, contraceptive skin patch or cervical ring) for at least 30 days prior to vaccination and until 30 days after final vaccination or be in a monogamous relationship with a male partner who has undergone a vasectomy at least 6 months prior to first dose of study agent.
6. Willingness to attend all scheduled visits and able to comply with all trial procedures (e.g., blood draws, completion of diary cards, return for follow-up visits, accessible by phone or pager, able to self-sample for assessment of asymptomatic shedding of HSV, and not planning on moving from study area).
7. Negative HIV test result determined with an approved FDA-approved test. Confirmatory testing may be required based on the initial assay used and the result.
8. Subject is willing not to use antiviral therapy less than or equal to 2 days before and less than or equal to 3 days after each injection.
9. Subject is willing to forgo receipt of a licensed, live vaccine in the 30 days preceding each dose of vaccine or in the 30 days following each dose of vaccine. The inactivated flu vaccine can be used greater than or equal to 14 days before or greater than or equal to 14 days after administration of study vaccine, if this is felt to be necessary.
10. Persons who have close contact with infants or immunocompromised individuals agree to avoid such contact for 3 days after each injection.
11. Subject must be either HSV-1 IgG antibody positive or negative and HSV-2 IgG antibody positive, HSV-1 IgG antibody positive /HSV-2 IgG antibody negative, or HSV-1/HSV-2 IgG antibody negative as determined by an available commercial immunoassay.
12. Subject must be willing to allow storage of blood, swabs of skin or mucosa, biopsies of skin lesions, or, for female subjects, cervicovaginal secretions (if collected) for future research.
Participation of Women:
Contraception: The effects of HSV529 on the developing human fetus are unknown. For this reason, females subjects must be of non-childbearing potential i.e. either surgically sterilized (bilateral tubal ligation, hysterectomy) or, if of child-bearing potential and sexually active with a male partner, she must be willing to use a highly effective method of contraception (e.g., intrauterine device (IUD); oral contraceptives diaphragm or condom in combination with contraceptive foam, jelly or cream; Norplant, DepoProvera, contraceptive skin patch or cervical ring) for at least 30 days prior to vaccination and until 1 month after final vaccination or be in a monogamous relationship with a male partner who has undergone a vasectomy at least 6 months prior to first dose of study agent. Females must have a negative urine pregnancy test result prior to injection with HSV529 or placebo. During the course of the study, if a woman becomes pregnant or suspects she is pregnant, she should inform the study staff and her primary care physician immediately.
Exclusion Criteria
Co-enrollment Guidelines: Co-enrollment in other trials is restricted, other than enrollment into observational studies or into the screening protocol. Study staff should be notified of co-enrollment as it may require the approval by the Principal Investigator.
An individual fulfilling any of the following criteria is to be excluded from trial enrollment:
1. Subject is pregnant or lactating OR planning to become pregnant timeframe that begins 30 days prior to the first vaccination and ends 30 days after the third vaccination.
2. Body Mass Index greater than 40.
3. Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination or or planned participation during the study period up to 6 months after the last dose of vaccine or placebo. The non-interventional follow-up for an earlier study (e.g., long-term surveillance) will be allowed.
4. Severe active infection or serious HSV-2 related or unrelated medical conditions that, in the opinion of the investigator, would prevent study completion.
5. Subjects with 6 or more symptomatic recurrences of genital herpes disease within the year prior to Day 0.
6. A history of HSV infection of the eye (e.g., herpes simplex interstitial keratitis or uveitis).
7. A history of herpes gladiatorum, herpetic whitlow or eczema herpeticum.
8. A history of lesions caused by HSV on either arm.
9. A history of herpes-associated erythema multiforme.
10. A history of a clinically significant autoimmune disorder.
11. Known or suspected congenital or acquired immunodeficiency
12. Receipt of anti-cancer chemotherapy or radiation therapy within the preceding 6 months.
13. Subjects using corticosteroids (excluding topical, inhaled or nasal) or any immunomodulating drugs within 42 days prior to the first vaccination. An immunosuppressive dose of corticosteroids is defined as greater than or equal to 10 mg prednisone equivalent per day for greater than or equal to 14 days.
14. Subjects without a spleen.
15. Subjects receiving immunoglobulin within the past 6 months or anticipated receipt of immunoglobulin during the 28 days following vaccination.
16. Bleeding disorder, or receipt of anticoagulants that, in the opinion of the Investigator, would interfere with the subject s participation in the trial.
17. Prior vaccination against herpes simplex virus.
18. Known allergy or intolerance to vaccine components \[e.g., potassium glutamate (possible cross-reaction to monosodium glutamate), sucrose\] or to a vaccine containing any of the same substances.
19. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
20. Current alcohol abuse or drug abuse or addiction.
21. Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
22. Employee of the NIH or contractor working at the NIH, with direct involvement in the proposed study as well as family members (i.e. immediate, husband, wife and their children, adopted or natural) of the employee or of the investigators of this study.
23. Any condition that the PI thinks might compromise the person s ability to comply with the requirements of the study.
Justification for Exclusion of Women and Children:
Exclusion of Women:
* Pregnancy: Pregnant women are excluded from this study because the effects of HSV529 on the developing human fetus are unknown with the potential for teratogenic or abortifacient effects.
* Breast-feeding: Because there is an unknown but potential risk for adverse events in nursing infants secondary to vaccination of the mother with HSV529, breastfeeding should be discontinued if the mother will be vaccinated with HSV529.
Exclusion of Children:
Because there are insufficient data regarding dosing or adverse events available in adults to judge the potential risk in children, children are excluded from this study.
An individual fulfilling any of the following criteria is to be excluded from trial enrollment:
1. Subject is pregnant or lactating OR planning to become pregnant timeframe that begins 30 days prior to the first vaccination and ends 30 days after the third vaccination.
2. Body Mass Index greater than 40.
3. Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination or or planned participation during the study period up to 6 months after the last dose of vaccine or placebo. The non-interventional follow-up for an earlier study (e.g., long-term surveillance) will be allowed.
4. Severe active infection or serious HSV-2 related or unrelated medical conditions that, in the opinion of the investigator, would prevent study completion.
5. Subjects with 6 or more symptomatic recurrences of genital herpes disease within the year prior to Day 0.
6. A history of HSV infection of the eye (e.g., herpes simplex interstitial keratitis or uveitis).
7. A history of herpes gladiatorum, herpetic whitlow or eczema herpeticum.
8. A history of lesions caused by HSV on either arm.
9. A history of herpes-associated erythema multiforme.
10. A history of a clinically significant autoimmune disorder.
11. Known or suspected congenital or acquired immunodeficiency
12. Receipt of anti-cancer chemotherapy or radiation therapy within the preceding 6 months.
13. Subjects using corticosteroids (excluding topical, inhaled or nasal) or any immunomodulating drugs within 42 days prior to the first vaccination. An immunosuppressive dose of corticosteroids is defined as greater than or equal to 10 mg prednisone equivalent per day for greater than or equal to 14 days.
14. Subjects without a spleen.
15. Subjects receiving immunoglobulin within the past 6 months or anticipated receipt of immunoglobulin during the 28 days following vaccination.
16. Bleeding disorder, or receipt of anticoagulants that, in the opinion of the Investigator, would interfere with the subject s participation in the trial.
17. Prior vaccination against herpes simplex virus.
18. Known allergy or intolerance to vaccine components \[e.g., potassium glutamate (possible cross-reaction to monosodium glutamate), sucrose\] or to a vaccine containing any of the same substances.
19. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
20. Current alcohol abuse or drug abuse or addiction.
21. Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
22. Employee of the NIH or contractor working at the NIH, with direct involvement in the proposed study as well as family members (i.e. immediate, husband, wife and their children, adopted or natural) of the employee or of the investigators of this study.
23. Any condition that the PI thinks might compromise the person s ability to comply with the requirements of the study.
Justification for Exclusion of Women and Children:
Exclusion of Women:
* Pregnancy: Pregnant women are excluded from this study because the effects of HSV529 on the developing human fetus are unknown with the potential for teratogenic or abortifacient effects.
* Breast-feeding: Because there is an unknown but potential risk for adverse events in nursing infants secondary to vaccination of the mother with HSV529, breastfeeding should be discontinued if the mother will be vaccinated with HSV529.
Exclusion of Children:
Because there are insufficient data regarding dosing or adverse events available in adults to judge the potential risk in children, children are excluded from this study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi Pasteur, a Sanofi Company
INDUSTRY
Sponsor Role
collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey I Cohen, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6994-8. doi: 10.1073/pnas.96.12.6994.
Reference Type
BACKGROUND
Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis. 2009 Oct 1;200(7):1088-95. doi: 10.1086/605645.
Reference Type
BACKGROUND
Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol. 2000 Sep;74(17):7963-71. doi: 10.1128/jvi.74.17.7963-7971.2000.
Reference Type
BACKGROUND
Cheung F, Apps R, Dropulic L, Kotliarov Y, Chen J, Jordan T, Langweiler M, Candia J, Biancotto A, Han KL, Rachmaninoff N, Pietz H, Wang K, Tsang JS, Cohen JI. Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine. Elife. 2023 Jan 17;12:e80652. doi: 10.7554/eLife.80652.
Reference Type
DERIVED
Dropulic LK, Oestreich MC, Pietz HL, Laing KJ, Hunsberger S, Lumbard K, Garabedian D, Turk SP, Chen A, Hornung RL, Seshadri C, Smith MT, Hosken NA, Phogat S, Chang LJ, Koelle DM, Wang K, Cohen JI. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. J Infect Dis. 2019 Aug 9;220(6):990-1000. doi: 10.1093/infdis/jiz225.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-I-0172.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-I-0172
Identifier Type: -
Identifier Source: secondary_id
130172
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
NCT04762511
TERMINATED
PHASE1
HerpeVac Trial for Young Women
NCT00057330
COMPLETED
PHASE3
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
NCT02030301
COMPLETED
PHASE1/PHASE2
Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines
NCT00698490
COMPLETED
PHASE1/PHASE2
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine
NCT00224471
COMPLETED
PHASE3
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
NCT02837575
COMPLETED
PHASE2
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults
NCT00698893
COMPLETED
PHASE1
A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease
NCT05500053
COMPLETED
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
NCT05432583
ACTIVE_NOT_RECRUITING
PHASE1
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
NCT05298254
COMPLETED
PHASE1/PHASE2
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
NCT02515175
COMPLETED
PHASE2
A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects
NCT05823779
UNKNOWN
Herpevac Neonatal Substudy
NCT00138320
TERMINATED
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
NCT01687595
COMPLETED
PHASE2
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
NCT01667341
COMPLETED
PHASE1/PHASE2
Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
NCT03661541
COMPLETED
PHASE1
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
NCT00224484
COMPLETED
PHASE3
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
NCT00001649
COMPLETED
PHASE3
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
NCT00274300
COMPLETED
PHASE1
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
NCT01827839
COMPLETED
PHASE3
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
NCT05989672
COMPLETED
PHASE1
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
NCT00946556
COMPLETED
NA
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
NCT00079911
TERMINATED
PHASE4